Beta-containing COVID-19 booster vaccine found to cross-neutralize variants in non-human primates

A new paper presents preliminary evidence that a new vaccine candidate, designed to boost immunity in already immunized individuals, and containing the adjuvanted Beta spike variant protein antigen, can induce a potent cross-neutralizing antibody response in non-human primate models that is detectable for up to three months.

COVID-19 vaccine - Wikipedia

Beta-containing COVID-19 booster vaccine found to cross-neutralize variants in non-human primates

Emergence of the SARS-CoV-2 Omicron Variant: Current Treatments and Vaccines for COVID-19

SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2 - ScienceDirect

Neutralizing antibodies to SARS-CoV-2 Omicron variant after 3rd mRNA vaccination in health care workers and elderly subjects and response to a single dose in previously infected adults

mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant

Vaccines, Free Full-Text

Omicron-specific mRNA vaccine generates immune responses in mice, hamsters and Macaques

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19